JP2016507581A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507581A5
JP2016507581A5 JP2015557539A JP2015557539A JP2016507581A5 JP 2016507581 A5 JP2016507581 A5 JP 2016507581A5 JP 2015557539 A JP2015557539 A JP 2015557539A JP 2015557539 A JP2015557539 A JP 2015557539A JP 2016507581 A5 JP2016507581 A5 JP 2016507581A5
Authority
JP
Japan
Prior art keywords
alkyl
group
pharmaceutically acceptable
halo
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015557539A
Other languages
English (en)
Japanese (ja)
Other versions
JP6505023B2 (ja
JP2016507581A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/058840 external-priority patent/WO2014128585A1/en
Publication of JP2016507581A publication Critical patent/JP2016507581A/ja
Publication of JP2016507581A5 publication Critical patent/JP2016507581A5/ja
Application granted granted Critical
Publication of JP6505023B2 publication Critical patent/JP6505023B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015557539A 2013-02-19 2014-02-06 Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 Active JP6505023B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766268P 2013-02-19 2013-02-19
US61/766,268 2013-02-19
PCT/IB2014/058840 WO2014128585A1 (en) 2013-02-19 2014-02-06 Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018231938A Division JP2019069966A (ja) 2013-02-19 2018-12-11 Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物

Publications (3)

Publication Number Publication Date
JP2016507581A JP2016507581A (ja) 2016-03-10
JP2016507581A5 true JP2016507581A5 (OSRAM) 2017-03-02
JP6505023B2 JP6505023B2 (ja) 2019-04-24

Family

ID=50151342

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015557539A Active JP6505023B2 (ja) 2013-02-19 2014-02-06 Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
JP2018231938A Pending JP2019069966A (ja) 2013-02-19 2018-12-11 Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018231938A Pending JP2019069966A (ja) 2013-02-19 2018-12-11 Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物

Country Status (30)

Country Link
US (2) US9120788B2 (OSRAM)
EP (1) EP2958915B1 (OSRAM)
JP (2) JP6505023B2 (OSRAM)
KR (1) KR20150119370A (OSRAM)
CN (1) CN105121439A (OSRAM)
AP (1) AP2015008663A0 (OSRAM)
AR (1) AR094702A1 (OSRAM)
AU (1) AU2014220351A1 (OSRAM)
BR (1) BR112015019276A2 (OSRAM)
CA (1) CA2900302C (OSRAM)
CL (1) CL2015002222A1 (OSRAM)
CR (1) CR20150425A (OSRAM)
CU (1) CU20150082A7 (OSRAM)
DO (1) DOP2015000201A (OSRAM)
EA (1) EA201591360A1 (OSRAM)
EC (1) ECSP15035278A (OSRAM)
ES (1) ES2638850T3 (OSRAM)
HK (1) HK1217945A1 (OSRAM)
IL (1) IL240672A0 (OSRAM)
MA (1) MA38333A1 (OSRAM)
MD (1) MD20150071A2 (OSRAM)
MX (1) MX2015010714A (OSRAM)
NI (1) NI201500112A (OSRAM)
PE (1) PE20151332A1 (OSRAM)
PH (1) PH12015501755A1 (OSRAM)
SG (1) SG11201505878UA (OSRAM)
TN (1) TN2015000347A1 (OSRAM)
TW (1) TW201443048A (OSRAM)
UY (1) UY35333A (OSRAM)
WO (1) WO2014128585A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
PT3177624T (pt) * 2014-08-06 2019-07-11 Pfizer Compostos de imidazopiridazina
ES2865330T3 (es) * 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA
JP6800885B2 (ja) 2015-04-29 2020-12-16 ヤンセン ファーマシューティカ エヌ.ベー. イミダゾピラジン及びピラゾロピリミジン、並びにampa受容体調節物質としてのこれらの使用
US10604484B2 (en) 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
CA2984290C (en) 2015-04-29 2022-03-01 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
MX389753B (es) 2015-06-17 2025-03-20 Pfizer Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa
AR107099A1 (es) * 2015-12-22 2018-03-21 Gruenenthal Gmbh Compuestos espiro-[indolin heterocicloalcano] como inhibidores de la fosfodiesterasa
CA3015166C (en) * 2016-02-23 2021-08-03 Pfizer Inc. 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
JP7050054B2 (ja) * 2016-08-22 2022-04-07 メッドシャイン ディスカバリー インコーポレイテッド Pde4阻害剤としての縮合環系化合物
WO2018234353A1 (en) 2017-06-20 2018-12-27 Grünenthal GmbH Novel substituted indole and indazole compounds as phosphodiesterase inhibitors
WO2018234354A1 (en) 2017-06-20 2018-12-27 Grünenthal GmbH Novel substituted 3-indole and 3-indazole compounds as phosphodiesterase inhibitors
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7601425B2 (ja) * 2020-03-31 2024-12-17 エルジー・ケム・リミテッド 膵島移植保護用組成物
CN112390750B (zh) * 2020-11-11 2022-03-01 常州大学 作为选择性磷酸二酯酶2抑制剂的喹啉酮类化合物及其制备方法

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
WO1994017197A1 (fr) 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
JPH08295667A (ja) * 1995-04-27 1996-11-12 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
JPH08295687A (ja) * 1995-04-28 1996-11-12 Ube Ind Ltd 無水シトラコン酸の製造法
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
EP2305709A1 (en) 1997-04-09 2011-04-06 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
CA2390948A1 (en) * 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PT1196408E (pt) 1999-06-28 2005-01-31 Janssen Pharmaceutica Nv Inibidores da replicacao do virus sincicial respiratorio
EP1244668B1 (en) 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
KR100767146B1 (ko) 2000-02-24 2007-10-15 워싱톤 유니버시티 Aβ 펩티드를 격리시키는 인간화 항체
ES2244613T3 (es) 2000-04-27 2005-12-16 Astellas Pharma Inc. Derivados de imidazopiridina.
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
NZ544691A (en) 2000-11-03 2007-12-21 Proteotech Inc Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
WO2003000697A1 (en) 2001-06-22 2003-01-03 Takeda Chemical Industries, Ltd. Furoisoquinoline derivative, process for producing the same, and use
ES2242036T3 (es) 2001-06-27 2005-11-01 MERCK FROSST CANADA & CO. Inhibidores pde4 de arilquinolina 8-sustituida.
US6943195B2 (en) 2001-06-29 2005-09-13 Nikken Chemicals Co., Ltd Cycloalkenone derivative
WO2003008396A1 (en) 2001-07-16 2003-01-30 Nikken Chemicals Co., Ltd. Optically active oxazine derivative
PL366792A1 (en) 2001-07-18 2005-02-07 Merck Patent Gmbh 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies
WO2003008373A1 (de) 2001-07-19 2003-01-30 Merck Patent Gmbh Tyrosinhydrazide
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
EP1285922A1 (en) 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
FR2828693B1 (fr) 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
WO2003015789A2 (en) 2001-08-15 2003-02-27 Leo Pharma A/S A pharmaceutical composition for dermal application
KR100957516B1 (ko) 2001-08-15 2010-05-14 이코스 코포레이션 2h-프탈라진-1-온 및 이것의 사용 방법
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
GB0122031D0 (en) 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
US20050014762A1 (en) 2001-09-19 2005-01-20 Rolf Beume Combination
DE60218497T2 (de) 2001-09-19 2007-11-08 Nycomed Gmbh Kombination eines nsaids und eines pde-4 inhibitors
WO2003035650A1 (en) 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Entry inhibitor
US6911543B2 (en) 2001-10-02 2005-06-28 Pfizer Inc. Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
GB0123951D0 (en) 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
DE10150517A1 (de) 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
US7235579B2 (en) 2001-10-16 2007-06-26 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
WO2003037860A2 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
EP1463509A1 (en) 2001-10-31 2004-10-06 MERCK PATENT GmbH Type 4 phosphodiesterase inhibitors and uses thereof
ATE541847T1 (de) 2001-11-01 2012-02-15 Icagen Inc Pyrazolopyrimidine als natriumkanalblocker
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
DE60213841T2 (de) 2001-11-05 2007-02-15 Merck Patent Gmbh Hydrazono-malonitrile
US20030092706A1 (en) 2001-11-09 2003-05-15 Johannes Barsig Combination
IS7221A (is) 2001-11-15 2004-04-15 Memory Pharmaceuticals Corporation Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
US20050101000A1 (en) 2002-12-11 2005-05-12 Isis Pharmaceuticals Inc. Modulation of phosphodiesterase 4B expression
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
MXPA05003621A (es) 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
WO2004042390A2 (en) 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
AU2003299651A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
ES2338656T3 (es) 2003-04-11 2010-05-11 High Point Pharmaceuticals, Llc Uso farmaceutico de 1,2,4-triazoles fusionados.
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
JP2006527756A (ja) 2003-06-19 2006-12-07 ファイザー・プロダクツ・インク Nk1拮抗薬
CA2530081A1 (en) 2003-07-01 2005-01-13 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
FR2857966A1 (fr) 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
GB0322726D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
CN101579529A (zh) 2003-09-29 2009-11-18 托皮根药品公司 治疗包括炎症状况的疾病的寡核苷酸组合物和方法
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
WO2005066151A2 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2555071A1 (en) 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
EP1742627A4 (en) 2004-05-06 2009-08-26 Plexxikon Inc PDE4B HEMMER AND ITS USE
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
CN101048407A (zh) 2004-09-03 2007-10-03 普莱希科公司 双环杂芳基pde4b抑制剂
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7547698B2 (en) 2004-09-20 2009-06-16 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)
KR20070057965A (ko) 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
FR2877015B1 (fr) 2004-10-21 2007-10-26 Commissariat Energie Atomique Revetement nanostructure et procede de revetement.
DE102004054634A1 (de) * 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
JPWO2006088246A1 (ja) 2005-02-18 2008-07-10 武田薬品工業株式会社 Gpr34受容体機能調節剤
GB0503955D0 (en) 2005-02-25 2005-04-06 Glaxo Group Ltd Novel compounds
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2608672A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006136924A1 (en) 2005-06-22 2006-12-28 Pfizer Products Inc. Histamine-3 receptor antagonists
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP2009514846A (ja) 2005-11-04 2009-04-09 ファイザー・リミテッド テトラヒドロナフチリジン誘導体
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
GB0605462D0 (en) 2006-03-17 2006-04-26 Glaxo Group Ltd Novel compounds
SI2013208T1 (sl) 2006-04-21 2011-09-30 Pfizer Prod Inc Piridin(3,4-b)pirazinoni
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8138205B2 (en) 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
MX2009000148A (es) 2006-07-07 2009-10-26 Kalypsys Inc Inhibidores heteroaril biciclicos de fosfodiesterasa 4.
MX2009001036A (es) 2006-08-04 2009-04-23 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas, proceso para su preparacion y su uso como medicina.
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
WO2008033739A2 (en) * 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
US20090275586A1 (en) 2006-10-06 2009-11-05 Kalypsys, Inc. Heterocyclic inhibitors of pde4
WO2008045663A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents
US20080102475A1 (en) 2006-10-13 2008-05-01 Zhengyan Kan Alternatively spliced isoform of phosphodiesterase 4B (PDE4B)
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
EP2124933B1 (en) 2007-01-22 2012-10-17 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
EA201000201A1 (ru) 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
WO2009023623A1 (en) 2007-08-10 2009-02-19 H, Lundbeck A/S Heteroaryl amide analogues
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
GB2461702A (en) 2008-07-08 2010-01-13 Dyson Technology Ltd Hand drying apparatus
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US8853125B2 (en) 2008-09-24 2014-10-07 Basf Se Pyrazole compounds for controlling invertebrate pests
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
AU2010224485B2 (en) 2009-03-20 2014-04-17 Hg&H Pharmaceuticals (Pty) Ltd Use of pharmaceutical compositions containing mesembrenone
EP2493889B1 (en) 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
EP2504340A1 (en) 2009-11-25 2012-10-03 Merz Pharma GmbH & Co. KGaA Crystalline forms of substituted pyrazolopyrimidines
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
EP2549874A4 (en) 2010-03-23 2013-10-02 High Point Pharmaceuticals Llc SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
AU2011253203A1 (en) 2010-05-10 2012-11-22 Gilead Sciences, Inc. Bifunctional quinoline derivatives
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
WO2013028263A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
US9193736B2 (en) 2013-06-11 2015-11-24 Janssen Pharmaceutica, Nv PDE 10a inhibitors for the treatment of type II diabetes
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US11497586B2 (en) 2014-03-21 2022-11-15 Align Technology, Inc. Segmented orthodontic appliance with elastics
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
PT3177624T (pt) 2014-08-06 2019-07-11 Pfizer Compostos de imidazopiridazina

Similar Documents

Publication Publication Date Title
JP2016507581A5 (OSRAM)
JP2018519323A5 (OSRAM)
JP2016525136A5 (OSRAM)
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
CA2983453A1 (en) Naphthyridine compounds as jak kinase inhibitors
JP2016525135A5 (OSRAM)
JP2016512520A5 (OSRAM)
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
JP2019524883A5 (OSRAM)
WO2015108490A3 (en) Heteroaryl alkyne derivatives and uses thereof
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
EA201001126A1 (ru) Пирролопиримидины и пирролопиридины
JP2019501125A5 (OSRAM)
JP2016540742A5 (OSRAM)
JP2014525937A5 (OSRAM)
JP2016535031A5 (OSRAM)
JP2016518317A5 (OSRAM)
CY1119231T1 (el) Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3
JP2016540749A5 (OSRAM)
HK1256242A1 (zh) 吲哚化合物以及製備和使用該化合物的方法
JP2015508092A5 (OSRAM)
GEP20207098B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
NZ702618A (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
JP2015528508A5 (OSRAM)
JP2017517538A5 (OSRAM)